Conundrums in Treating HER2-Positive Early Breast Cancer

1. The abundance of therapies for HER2-positive early breast cancer presents a challenge in selecting the most suitable treatment. 2. Treatment of patients with small tumors and negative lymph nodes remains controversial, with considerations for adjuvant systemic therapy and chemotherapy. 3. Neoadjuvant therapy is recommended for high-risk patients with T1c or clinically node-positive tumors, based on results from the KATHERINE trial. 4. Dr. Hurvitz emphasizes the avoidancen of anthracyclines due to limited benefits and potential cardiac damage. 5. The use of response-guided approaches, such as PET-adapted response and MRI, is being explored to improve treatment outcomes for HER2-positive breast cancer.